九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02566 九源基因

午间休市 03-20 10:28:37

8.130

-0.110

-1.33%

最高8.380	最低8.030	成交量2.82万
今开8.380	昨收8.240	日振幅4.25%
总市值19.67亿	流通市值8.62亿	总股本2.42亿
成交额23.04万	换手率0.03%	流通股本1.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02566","market":"HK","secType":"STK","nameCN":"九源基因","latestPrice":8.13,"timestamp":1773973717699,"preClose":8.24,"halted":0,"volume":28200,"delay":0,"changeRate":-0.013349514563106726,"floatShares":106000000,"shares":242000000,"eps":0.678655,"marketStatus":"午间休市","change":-0.11,"latestTime":"03-20 10:28:37","open":8.38,"high":8.38,"low":8.03,"amount":230416,"amplitude":0.042476,"askPrice":8.13,"askSize":1400,"bidPrice":8.04,"bidSize":200,"shortable":0,"etf":0,"ttmEps":0.559,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773982800000},"marketStatusCode":3,"adr":0,"listingDate":1732723200000,"exchange":"SEHK","adjPreClose":8.24,"dividendRate":0.007757,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":2.241329,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02566","defaultTab":"news","newsList":[{"id":"1125248160","title":"九源基因（02566）公布1月股份变动月报，合计回购约77.44万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=1125248160","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125248160?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:21","pubTimestamp":1773829312,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年3月18日披露2026年1月股份变动月报表，报告期为2026年1月。截至本月末，公司注册股本人民币245,398,800元，其中包括三类股份：H股、内资股及非上市外资股。H股方面，月初已发行流通股份数量为109,096,785股，当月合计回购774,400股，并将其持作库存股份，导致H股流通股份减少至108,322,385股，库存股份则增至774,400股。内资股和非上市外资股数量分别维持在105,302,015股及31,000,000股，报告期内无变动。截至1月末，公司股本总数保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2620430440","title":"九源基因(02566)：JY47注射液新药临床试验申请获国家药监局临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2620430440","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620430440?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:21","pubTimestamp":1773739274,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，集团自主开发的JY47注射液新药临床试验(IND)申请已获中国国家药品监督管理局临床试验默示许可，适应症为代谢功能障碍相关脂肪性肝炎(MASH)伴肝纤维化。该产品为集团研发的一款靶向SIRPα的单抗注射液。SIRPα是典型的抑制性受体，可与配体CD47以高亲和力结合。研究表明CD47-SIRPα信号通路在代谢性疾病相关的免疫调控中具有重要作用，SIRP拮抗剂可通过调节免疫细胞功能、改善组织微环境及代谢稳态，从而对代谢疾病进展产生积极影响。在MASH的体外类器官模型和体内疾病模型中，显示出良好的治疗潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414914.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1110359935","title":"九源基因Jy47注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1110359935","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110359935?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:20","pubTimestamp":1773739217,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其Jy47注射液的临床试验申请已获得国家药品监督管理局的正式批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2617854431","title":"九源基因(02566.HK)公众持股量约为22.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617854431","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617854431?lang=zh_cn&edition=full","pubTime":"2026-03-05 20:07","pubTimestamp":1772712421,"startTime":"0","endTime":"0","summary":"格隆汇3月5日丨九源基因(02566.HK)公告，于本公告日期，公司的公众持股量约为22.22%，已低于上市规则第19A.28B条所规定公众股东持有公司已发行股份总数的25.0%(\"最低规定百分比\")。\r\n\r\n　　公司公众持股量的不足，乃由于近期根据公司股东于2025年6月11日举行的股东周年大会上授予董事会的购回授权，回购公司H股所致，使得其中一名公众股东转变成为上市规则所定义的主要股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260305/32047782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1152661765","title":"九源基因(02566)公告：公众持股量降至22.22% 正研究恢复至25%最低比例","url":"https://stock-news.laohu8.com/highlight/detail?id=1152661765","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152661765?lang=zh_cn&edition=full","pubTime":"2026-03-05 19:51","pubTimestamp":1772711502,"startTime":"0","endTime":"0","summary":"九源基因于2026年3月5日发布公告，指出上市公司公众持股量约为22.22%，低于香港联合交易所有限公司证券上市规则所要求的最低25%规定。据悉，主要原因在于根据2025年6月11日股东周年大会上授予董事会的购回授权回购H股后，一名原本属于公众持股范围的股东转变为上市规则定义的主要股东，导致公众持股量减少。公司预计自公告日期起六个月内恢复公众持股量，但仍需董事会和监管机构批准，并视乎市场情况而定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2616443314","title":"九源基因盘中异动 快速上涨7.98%报9.200港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616443314","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616443314?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:31","pubTimestamp":1772501508,"startTime":"0","endTime":"0","summary":"2026年03月03日早盘09时31分，九源基因股票出现异动，股价急速上涨7.98%。截至发稿，该股报9.200港元/股，成交量3200股，换手率0.00%，振幅0.00%。资金方面，该股资金流入2.944万港元，流出0港元。九源基因股票所在的药品行业中，整体跌幅为0.01%。其相关个股中，九源基因、联邦制药、英硅智能涨幅较大，振幅较大的相关个股有长风药业、宝济药业-B、英硅智能，振幅分别为4.31%、2.58%、2.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303093148a69aff13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260303093148a69aff13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2614029090","title":"国产减重药迎突破！九源基因司美格鲁肽申报上市 瞄准百亿美元赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029090","media":"大湾区经济网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614029090?lang=zh_cn&edition=full","pubTime":"2026-02-26 10:12","pubTimestamp":1772071957,"startTime":"0","endTime":"0","summary":"在国内司美格鲁肽减重适应症领域，公司属于少数已完成上市申报并进入审评阶段的企业之一。相关产品如顺利获批，有望成为国内首个以生物法实现产业化的司美格鲁肽减重药物。公开数据显示，司美格鲁肽减重产品在中国市场实现快速增长，2025年诺和诺德司美格鲁肽减重版注射液中国区销售额为1.21亿美元，同比激增314%，市场对高品质减重药物的需求日益迫切。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226101341a4c95f06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260226101341a4c95f06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2614608029","title":"九源基因(02566)：吉可亲®上市申请获国家药品监督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2614608029","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614608029?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:44","pubTimestamp":1772027076,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，集团开发的吉可亲的上市申请已获中国国家药监局受理。吉可亲于2024年1月获得国家药品监督管理局签发的药物临床试验批准通知书，并于2024年12月完成Ⅲ期临床研究全部受试者入组，目前已完成试验，上市申请相关申报资料已递交国家药品审评中心进行审评。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九源基因(02566)：吉可亲®上市申请获国家药品监督管理局受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"2614741093","title":"九源基因盘中异动 下午盘快速下挫6.47%报8.680港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614741093","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614741093?lang=zh_cn&edition=full","pubTime":"2026-02-24 13:30","pubTimestamp":1771911026,"startTime":"0","endTime":"0","summary":"2026年02月24日下午盘13时30分，九源基因股票出现异动，股价大幅下挫6.47%。截至发稿，该股报8.680港元/股，成交量1.52万股，换手率0.01%，振幅5.60%。资金方面，该股资金流入7192港元，流出13.0192万港元。九源基因股票所在的药品行业中，整体跌幅为0.64%。其相关个股中，宝济药业-B、三爱健康集团、海西新药涨幅较大，振幅较大的相关个股有宝济药业-B、君圣泰医药-B、英硅智能，振幅分别为10.83%、8.84%、8.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022413302697a6cba4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022413302697a6cba4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2613733439","title":"九源基因2026年关注点：司美格鲁肽专利到期与新品临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2613733439","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613733439?lang=zh_cn&edition=full","pubTime":"2026-02-23 17:43","pubTimestamp":1771839834,"startTime":"0","endTime":"0","summary":"来源：经济观察网经济观察网 根据公开信息，九源基因在2026年有以下值得关注的事件：行业政策与环境司美格鲁肽专利到期及市场竞争变化：司美格鲁肽核心专利将于2026年3月后到期，预计国产司美格鲁肽将进入市场竞争加剧的阶段，九源基因是申报该产品的企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223174806a7158f38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223174806a7158f38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2613207749","title":"九源基因盘中异动 股价大涨8.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613207749","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613207749?lang=zh_cn&edition=full","pubTime":"2026-02-23 09:31","pubTimestamp":1771810290,"startTime":"0","endTime":"0","summary":"2026年02月23日早盘09时31分，九源基因股票出现波动，股价急速上涨8.49%。截至发稿，该股报9.970港元/股，成交量1.1万股，换手率0.01%，振幅0.00%。九源基因股票所在的药品行业中，整体涨幅为0.27%。其相关个股中，九源基因、德琪医药-B、长风药业涨幅较大，振幅较大的相关个股有康龙化成、康哲药业、中国同辐，振幅分别为3.48%、2.38%、2.34%。九源基因公司简介：杭州九源基因工程有限公司是一家主要从事基因药物研发的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931309541a2c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602230931309541a2c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2610794209","title":"九源基因(02566)2月12日耗资约25.53万港元回购2.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610794209","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610794209?lang=zh_cn&edition=full","pubTime":"2026-02-12 19:03","pubTimestamp":1770894192,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)公布，2026年2月12日耗资约25.53万港元回购2.6万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404787.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"2610936857","title":"九源基因(02566)2月11日斥资8.51万港元回购8600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610936857","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610936857?lang=zh_cn&edition=full","pubTime":"2026-02-11 18:54","pubTimestamp":1770807244,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，该公司于2026年2月11日斥资8.51万港元回购8600股股份，每股回购价格为9.89-9.9港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02566"],"gpt_icon":0},{"id":"1103066878","title":"杭州九源基因(02566)回购约28.52万股H股，总额约287万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103066878","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103066878?lang=zh_cn&edition=full","pubTime":"2026-02-10 19:01","pubTimestamp":1770721311,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司(02566)于2026年2月10日发布翌日披露报表，披露当日回购285,200股H股，占回购前公司已发行股份（不包括库藏股）的约0.27024%。\n本次回购于香港联交所进行，价格区间介于每股9.83港元至10.30港元之间，合计支付约2,870,506.048港元。根据2025年6月11日获通过的购回授权，公司剩余可回购股份数为10,909,678股。回购完成后，公司已发行股份总数维持在109,096,785股，其中流通股为105,248,985股，库藏股为3,847,800股。\n公司确认已严格遵守相关上市规则及法律规定。公告由联席公司秘书黄秀签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2610756637","title":"九源基因(02566)2月9日斥资60.59万港元回购6.08万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610756637","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610756637?lang=zh_cn&edition=full","pubTime":"2026-02-09 20:13","pubTimestamp":1770639185,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因(02566)发布公告，于2026年2月9日，该公司斥资60.59万港元回购6.08万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","BK1161"],"gpt_icon":0},{"id":"1194403275","title":"杭州九源基因（02566）回购6.08万股股份，总额约60.59万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194403275","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194403275?lang=zh_cn&edition=full","pubTime":"2026-02-09 19:51","pubTimestamp":1770637908,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司于2026年2月9日公布翌日披露报表，披露当日回购60,800股H股股份，约占回购前已发行股本的0.05758%。本次回购每股价格在每股港币9.81元至10元区间，总额约港币60.59万元。据公告显示，本次回购基于2025年6月11日通过的回购授权进行，公司目前可回购股份总数为10,909,678股，截至公告日已回购3,562,600股。公司确认已遵守香港联合交易所有限公司证券上市规则及相关法律规定。公告由联席公司秘书黄秀签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2610600638","title":"九源基因(02566)：JY54注射液IND申请获CDE正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600638","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610600638?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:56","pubTimestamp":1770627414,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，公司自主开发的化学1类创新药JY54 注射液新药临床试验申请，已获国家药品监督管理局药品审评中心正式受理。JY54注射液是公司自主研发的一款长效胰淀素类似物。此外，在与已上市肥胖治疗药物的联合应用研究中，JY54注射液展现出显著的药物协同潜力。基于其分子设计特点及作用机制分析，JY54注射液有望支持长效给药方案，并在体重管理领域展现差异化的临床应用潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4017","IND","LU1223082519.USD","CDE","LU1223082196.USD","02566","LU1223083913.SGD"],"gpt_icon":0},{"id":"1111776355","title":"九源基因Jy54注射液临床试验申请获国家药监局药品审评中心受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1111776355","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111776355?lang=zh_cn&edition=full","pubTime":"2026-02-09 16:53","pubTimestamp":1770627193,"startTime":"0","endTime":"0","summary":"杭州九源基因工程股份有限公司宣布，其研发的Jy54注射液新药临床试验（IND）申请，已正式获得国家药品监督管理局药品审评中心（CDE）的受理。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566","BK1161"],"gpt_icon":0},{"id":"1186606364","title":"杭州九源基因（02566）回购7.92万股H股，涉资约79万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186606364","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186606364?lang=zh_cn&edition=full","pubTime":"2026-02-06 19:33","pubTimestamp":1770377612,"startTime":"0","endTime":"0","summary":"杭州九源基因生物医药股份有限公司（02566）于2026年2月6日发布公告，披露当日回购H股79,200股，占回购前已发行股份的约0.07495%。本次回购价格介乎每股9.88港元至10港元，合计支付约790,449.98港元。\n经本次回购后，公司已发行股份（不包括库存股份）数目变更为105,594,985股，库存股份增至3,501,800股。公司于2025年6月11日通过的购回授权总数为10,909,678股，截至目前已回购股份合计3,501,800股。\n公司确认本次回购已依据董事会授权，并遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由联席公司秘书黄秀签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02566"],"gpt_icon":0},{"id":"2609737452","title":"九源基因(02566.HK)2月5日耗资877.3万港元回购85.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609737452","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609737452?lang=zh_cn&edition=full","pubTime":"2026-02-05 19:47","pubTimestamp":1770292023,"startTime":"0","endTime":"0","summary":"格隆汇2月5日丨九源基因(02566.HK)公告，2月5日耗资877.3万港元回购85.4万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260205/32001587.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","02566"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.china-gene.com","stockEarnings":[{"period":"1week","weight":0.0564},{"period":"1month","weight":-0.1399},{"period":"3month","weight":0.066},{"period":"6month","weight":-0.3133},{"period":"1year","weight":0.1478},{"period":"ytd","weight":0.0899}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0074},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0294},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"杭州九源基因生物医药股份有限公司（原名：杭州九源基因工程股份有限公司）是一家主要从事研发、生产及商业化生物药品和医疗器械的中国公司。该公司专注于骨科、代谢疾病、肿瘤及血液治疗领域。该公司的骨科产品包括骨优导骨修复材料。该公司的肿瘤产品包括吉利芬、吉巨芬、吉欧停、吉芙惟、吉坦苏。该公司的血液产品包括吉派林、亿喏佳。该公司的产品主要用于治疗糖尿病、多发性骨髓瘤、血小板减少症、中性粒细胞减少症等疾病。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"九源基因","nameEN":"JIUYUAN GENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九源基因(02566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九源基因,02566,九源基因股票,九源基因股票老虎,九源基因股票老虎国际,九源基因行情,九源基因股票行情,九源基因股价,九源基因股市,九源基因股票价格,九源基因股票交易,九源基因股票购买,九源基因股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九源基因(02566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九源基因(02566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}